Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calderasib - Merck Sharp & Dohme Corp.

Next Previous
Drug Profile

Calderasib - Merck Sharp & Dohme Corp.

Alternative Names: MK-1084

Latest Information Update: 11 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme Corp.
  • Class Alkanes; Alkenes; Antineoplastics; Chlorinated hydrocarbons; Cyclic ethers; Fluorobenzenes; Heterocyclic compounds with 4 or more rings; Ketones; Piperazines; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 06 Oct 2025 Merck Sharp & Dohme plans a phase II ​KANDLELIT-014/MK-1084-014 trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) (PO) in November 2025 (NCT07209111)
  • 30 Sep 2025 Merck Sharp & Dohme plans a phase III ​KANDLELIT-007/MK-1084-007 trial for Non small cell lung cancer (Combination therapy, Late-stage disease (SC) in October 2025 (NCT07190248)
  • 16 Jul 2025 Phase-III clinical trials in Adenocarcinoma (Combination therapy, Inoperable/Unresectable, First-line therapy, Metastatic disease, Late-stage disease) in Israel (PO) (NCT06997497)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top